DUBLIN, June 23, 2021 /CNW/ -- Medtronic
plc (NYSE: MDT), the global leader in medical technology,
today announced its participation at the American Diabetes
Association (ADA) 81th scientific sessions virtual
meeting, June 25-29, 2021. Medtronic
will be participating in this year's ADA virtual sessions with
seven data presentations, a product theater, two on-demand learning
sessions, and a virtual exhibit. This year Medtronic will showcase
its most advanced product portfolio designed to help individuals
achieve better glucose control and spend less time managing highs
and lows with the right solution, at the right time, no matter
where an individual is on their journey with diabetes.
Scientific Presentations
The following poster and oral
scientific data presentations represent the work of Medtronic
employees and/or independent investigators using Medtronic devices
in their research. Poster presentations will be available to
all attendees for viewing with an option to query presenters
throughout the conference.
InPen™ Smart Insulin Pen
- "Impact of InPen™ smart insulin pen use on real-world glycemic
and insulin dosing outcomes in individuals with poorly controlled
diabetes" – oral presentation by Robert Vigersky, M.D. on
Sunday, June 27 at 6:15 p.m. ET.
- "Glycemic outcomes of new InPen™ smart insulin pen users who
received virtual onboarding" – poster presentation by Madison Smith, Ph.D., R.N.
Medtronic Extended Infusion Set*
- "Infusion Set Survival and Performance During the Medtronic
Extended-Wear Infusion Set (EWIS) Pivotal Trial" – poster
presentation by Bruce Buckingham,
M.D.
- "Patient Reported Satisfaction During the Medtronic
Extended-Wear Infusion Set (EWIS) Pivotal Trial" – poster
presentation by Ron Brazg, M.D.,
FACE.
Hybrid Closed-Loop (HCL)
- "Closed-Loop Increases Time-in-Range in Older Adults with Type
1 Diabetes Compared with Sensor- Augmented Pump Therapy: A
Randomized Crossover Trial" – independent oral presentation by
Sybil McAuley, MBBS, Ph.D., FRACP,
on Sunday, June 27 at 4:30 p.m. ET.
- "Durable insulin pumps vs. multiple daily injections for type 1
diabetes: Healthcare utilization and A1C" – poster presentation by
Mona Shah, M.S.
Advanced Hybrid Closed-Loop (AHCL)*
- "Robust glycemic outcomes after MiniMed™ Advanced Hybrid
Closed-Loop (AHCL) System use regardless of previous therapy" –
poster presentation by John Shin,
Ph.D., MBA.
Conference Events
Medtronic will host a product
theater and offer two on-demand Learning Bytes that will focus on
the outcomes to date with InPen™ and the MiniMed™ 770G and MiniMed™
780G systems. The product theatre will also feature a patient panel
and a look at the Medtronic technology roadmap.
- "Shared Decision with Diabetes Technology" - product theater
live on Friday, June 25 at
10:00 a.m. ET then available
on-demand. Speakers and topics to be presented will include:
Janice
MacLeod,
M.A., R.D., CDCES,
FADCES,
head of clinical
advocacy,
Medtronic
Diabetes
|
Introduction and
Insulin 100
|
Diana
Isaacs,
PharmD, BCPS, BC-ADM,
CDCES, FADCES
Cleveland
Clinic
|
Smart MDI
Therapy: Smart Insulin Pens and CGM are Improving MDI
Therapy
|
Robert
Vigersky,
M.D. and chief
medical officer,
global medical &
clinical affairs, Medtronic
Diabetes
|
MiniMed™ 770G and
780G Systems: Proven Outcomes in Clinical Trials and
Real-World Data in Pediatric and Adult Populations
|
Diana
Isaacs,
PharmD, BCPS, BC-ADM,
CDCES, FADCES
|
Patient Ambassador
Panel
|
Ali
Dianaty,
vice president,
product innovation,
Medtronic
Diabetes
|
Looking Toward the
Future: Next Steps in the Advancement of Closing the
Loop
|
Janice
MacLeod,
M.A., R.D., CDCES,
FADCES,
head of clinical
advocacy,
Medtronic
Diabetes
|
Q & A
|
- "Tips for Success When Transitioning Patient from Multiple
Daily Injection (MDI) to Insulin Pump Therapy" – on-demand Learning
Byte presented by Laurie Jung, R.D.,
CDCES, opening on Thursday, June 24
at 8:00 a.m. ET.
- "InPen™ Smart Insulin Pen: Product Features and Overview" –
on-demand Learning Byte presented by Diana
Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES, opening on
Thursday, June 24 at 8:00 a.m. ET.
In addition, the Medtronic 24-hour virtual exhibit booth will
feature the company's full portfolio of diabetes technologies,
spanning smart MDI therapy with the InPen smart insulin pen system
and advanced insulin pump technology like the MiniMed 770G insulin
pump system. The exhibit will also highlight personalized service
and support offerings, including those that enable remote and
virtual care.
About the Diabetes Business at Medtronic
(www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care, and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com),
headquartered in Dublin, Ireland,
is among the world's largest medical technology, services and
solutions companies – alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals, and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
*CAUTION – Investigational device. Limited by U.S. law to
investigational use. Not approved or cleared by United States Food
and Drug Administration (FDA) and not for sale in the U.S.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
Kendra Cassillo
Public Relations
+1-818-576-5611
Ryan Weispfenning
Investor Relations
+1-763-505-4626
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medtronic-announces-real-world-data-on-inpen-and-extended-infusion-set-pivotal-trial-data-at-the-american-diabetes-association-81st-scientific-sessions-301317852.html
SOURCE Medtronic plc